Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4NET 1Gynecologic 1Endocrine 1

Conditions

Ovarian Neoplasms 323Fallopian Tube Neoplasms 159Carcinoma, Ovarian Epithelial 114Endometrial Neoplasms 77Uterine Cervical Neoplasms 72Neoplasms 28Carcinoma, Non-Small-Cell Lung 24Breast Neoplasms 23Brenner Tumor 21Recurrence 19Testicular Neoplasms 17Peritoneal Neoplasms 17Stomach Neoplasms 14Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Urinary Bladder Neoplasms 10Testicular Germ Cell Tumor 10Sarcoma 10Pancreatic Neoplasms 10Lung Neoplasms 10Colorectal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Parkinson Disease 4, Autosomal Dominant Lewy Body 9Teratoma 8Ovarian Germ Cell Cancer 8Neuroectodermal Tumors, Primitive, Peripheral 8Central Nervous System Neoplasms 8Uterine Neoplasms 7Small Cell Lung Carcinoma 7Melanoma 7

Interventions

pembrolizumab 2belinostat 2taxane 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Gemcitabine 1Fluorouracil 1Etoposide 1Drug Therapy 1Cisplatin 1Carboplatin 1Biological Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Carboplatin × Gynecologic × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡